Investment Thesis — BioMarin Pharmaceutical Inc.
The market is underpricing BioMarin's durable rare disease franchise and its compounding growth potential, fixating on a perceived lack of immediate blockbuster catalysts. This overlooks the steady cash flow generation and strategic pipeline advancements that are building long-term value, creating a resilient growth engine.
Catalysts
- Positive Phase 3 clinical trial results for a key gene therapy program (e.g., for PKU or other rare conditions).
- Regulatory approval or label expansion for Voxzogo in new age groups or geographies, significantly expanding its addressable market.
- Stronger-than-anticipated sales growth and market penetration for existing rare disease therapies, exceeding consensus estimates.
Risk Factors
- Clinical trial failures or significant regulatory delays for late-stage pipeline candidates.
- Increased competition or unexpected pricing pressure in key rare disease markets.
- Unfavorable reimbursement decisions or unexpected safety concerns for established products.
Key Debates
Voxzogo drives 15%+ revenue growth by Q4 2024
BMN 307 Phase 3 success elevates P/E to 18x by H1 2025
Operating margin expands 200bps by Q3 2024, raising analyst target